Picture EBD Group BIO-Europe Spring 2021 Digital 650x80
Document › Details

Confo Therapeutics N.V.. (12/19/17). "Press Release: Confo Therapeutics Enters into Drug Discovery Collaboration with Roche". Ghent.

Region Region ALL
Organisations Organisation Confo Therapeutics N.V.
  Organisation 2 Roche (Group)
Products Product drug discovery services
  Product 2 GPCR agonist
Index term Index term Roche–Confo Therapeutics: drug discovery services, 201712–202005 collab up to €87.5m plus milestones r+d + commerc small molecule GPCR agonists
Person Person Ververken, Cedric (Confo Therapeutics 201610– CEO before Ablynx)

Confo Therapeutics, an emerging drug discovery company, announced today that it has entered into a research collaboration and license agreement with Roche for the discovery, development and commercialisation of novel, small molecule agonists of an undisclosed G-protein coupled receptor (GPCR) for the treatment of neurological and developmental disorders.

Under the terms of the agreement, Roche gains exclusive rights to the compounds resulting from the collaboration and will be responsible for their development, manufacturing and commercialisation. The financial terms include an upfront payment, pre-clinical milestones and research funding to Confo Therapeutics totaling €6 million over the initial 30 months period of the collaboration. In addition, Confo Therapeutics is eligible to receive up to €81.5 million of payments for certain development, regulatory and commercial milestones, plus tiered royalties on the annual net sales of any products resulting from the collaboration.

“Securing this partnership with Roche is another significant corporate milestone for Confo Therapeutics,” said Dr. Cedric Ververken, CEO. “The decision by a global pharmaceutical company to work with Confo Therapeutics further validates the strength of our proprietary Confo technology and the capabilities of our team. It also strengthens our resolve to vigorously pursue our own proprietary product pipeline in addition to enabling our partners to develop valuable medicines for patients.”

More information:

About Confo Therapeutics

Confo Therapeutics is a VUB-VIB spin-off co-founded in 2015 by VIB and Capricorn Venture Partners with the support of MINTS, PMV, QBIC and V-Bio Ventures. Confo Therapeutics is a drug discovery company building a portfolio of first-in-class programs based on its proprietary Confo® technology, using antibody fragments or “Confobodies” to lock inherently unstable functional conformations of GPCRs as a superior starting point for drug discovery.

G-protein coupled receptors (GPCRs) are attractive drug targets in the treatment of many different conditions, playing an essential part in numerous life processes and influencing diseases. GPCRs are flexible signaling switches located in the cell membrane and pass outside signals into the cell through conformational changes.

More info:

Record changed: 2018-01-08


Picture ConsulTech GmbH RnD Credit Germany 650x80px

More documents for Confo Therapeutics N.V.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BIO-Europe Spring 2021 Digital 650x80

» top